Introduction
Amebiasis is a disease caused by a unicellular parasitic
protozoan E. histolytica. The World Health Organization
estimates that approximately 50 million people worldwide
sufferfrom invasive amebic infection,resulting in 40 to 100
thousand deaths annually [1]. Only metronidazole and
related compounds are commonly used against invasive
intestinal and extraintestinal amebiasis [2]. Although
clinical resistance against metronidazole has not yet been
demonstrated, a few limitations including low efficacy
against asymptomatic cyst carriers and sporadic cases of
treatment failure have been reported [2].In addition, it has
been shown that this parasite adapts to subtherapeutic
levels of metronidazole in vitro [3]. Therefore, the development
of a novel prophylactics and chemotherapeutics